Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1-Reference-Cited by-同舟云学术

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Published:2015-03-24 Issue:12 Volume:313 Page:1223
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Sulkowski Mark S.¹,Eron Joseph J.²,Wyles David³,Trinh Roger⁴,Lalezari Jay⁵,Wang Chia⁶,Slim Jihad⁷,Bhatti Laveeza⁸,Gathe Joseph⁹,Ruane Peter J.¹⁰,Elion Richard¹¹,Bredeek Fritz¹²,Brennan Robert¹³,Blick Gary¹⁴,Khatri Amit⁴,Gibbons Krystal⁴,Hu Yiran B.⁴,Fredrick Linda⁴,Schnell Gretja⁴,Pilot-Matias Tami⁴,Tripathi Rakesh⁴,Da Silva-Tillmann Barbara⁴,McGovern Barbara⁴,Campbell Andrew L.⁴,Podsadecki Thomas⁴

Affiliation:

1. Johns Hopkins University, Baltimore, Maryland

2. University of North Carolina, Chapel Hill

3. University of California, San Diego, La Jolla

4. AbbVie, North Chicago, Illinois

5. Quest Clinical Research, San Francisco, California

6. Virginia Mason Medical Center, Seattle, Washington

7. St Michael’s Medical Center, Newark, New Jersey

8. AIDS Healthcare Foundation, Beverly Hills, California

9. Cure C. Consortium, Houston, Texas

10. Ruane Medical and Liver Health Institute, Los Angeles, California

11. Whitman-Walker Health, Washington, DC